| Literature DB >> 25501582 |
Julia C Durrant1, Holly E Hinson.
Abstract
Vasospasm and delayed cerebral ischemia remain to be the common causes of increased morbidity and mortality after aneurysmal subarachnoid hemorrhage. The majority of clinical vasospasm responds to hemodynamic augmentation and direct vascular intervention; however, a percentage of patients continue to have symptoms and neurological decline. Despite suboptimal evidence, clinicians have several options in treating refractory vasospasm in aneurysmal subarachnoid hemorrhage (aSAH), including cerebral blood flow enhancement, intra-arterial manipulations, and intra-arterial and intrathecal infusions. This review addresses standard treatments as well as emerging novel therapies aimed at improving cerebral perfusion and ameliorating the neurologic deterioration associated with vasospasm and delayed cerebral ischemia.Entities:
Mesh:
Year: 2015 PMID: 25501582 PMCID: PMC4282184 DOI: 10.1007/s11910-014-0521-1
Source DB: PubMed Journal: Curr Neurol Neurosci Rep ISSN: 1528-4042 Impact factor: 5.081